Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B

A novel inhibitor of angiogenesis

Koichiro Tanaka, Takeshi Morii, Lawrence Weissbach, Keisuke Horiuchi, Katsuhito Takeuchi, Yoshiaki Toyama, Hideo Morioka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: We have previously reported that recombinant human plasminogen-related protein B (rPRP-B), a putative 9-kDa protein that closely resembles the activation peptide of plasminogen, has shown significant inhibition of tumor growth through inhibition of angiogenesis. Based on recent reports suggesting a close relationship between rheumatoid arthritis (RA) and angiogenesis, we hypothesized that this compound would regulate inflammatory conditions in RA. The present study therefore tested the effects of rPRP-B in the treatment of collagen-induced arthritis (CIA) to elucidate the mechanisms underlying these effects. Methods: DBA/1J mice immunized with type II collagen to induce CIA were monitored to assess the effects of rPRP-B on clinical severity of the disease. Pathological changes in joints, including vessel formation and vascular endothelial growth factor (VEGF) production, were examined histologically. Bone destruction was radiologically evaluated. In vitro studies on the effects of rPRP-B on cell proliferation and production of VEGF in interleukin (IL)-1β or basic fibroblast growth factor (bFGF)-stimulated human synoviocytes were also performed. Results: Development of CIA was effectively inhibited by rPRP-B. Radiological examinations revealed that the protein reduced bone destruction in CIA. CIA-induced vessel formation and VEGF expression in vivo were also reduced. In vitro mechanistic studies demonstrated that rPRP-B affected human synoviocyte proliferation and VEGF production stimulated by IL-1β and bFGF. Conclusions: Given the ability to effectively promote multistep anti-angiogenic activities, including cell growth inhibition and cytokine regulation, rPRP-B represents a promising candidate for a novel therapeutic agent against RA.

Original languageEnglish
Pages (from-to)443-450
Number of pages8
JournalJournal of Orthopaedic Science
Volume16
Issue number4
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

Angiogenesis Inhibitors
Experimental Arthritis
Plasminogen
Vascular Endothelial Growth Factor A
Rheumatoid Arthritis
Fibroblast Growth Factor 2
Interleukin-1
Bone and Bones
Inbred DBA Mouse
Collagen Type II
Growth
human PLGLB1 protein
IgA receptor
Proteins
Joints
Cell Proliferation
Cytokines
Peptides
Neoplasms

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B : A novel inhibitor of angiogenesis. / Tanaka, Koichiro; Morii, Takeshi; Weissbach, Lawrence; Horiuchi, Keisuke; Takeuchi, Katsuhito; Toyama, Yoshiaki; Morioka, Hideo.

In: Journal of Orthopaedic Science, Vol. 16, No. 4, 07.2011, p. 443-450.

Research output: Contribution to journalArticle

Tanaka, Koichiro ; Morii, Takeshi ; Weissbach, Lawrence ; Horiuchi, Keisuke ; Takeuchi, Katsuhito ; Toyama, Yoshiaki ; Morioka, Hideo. / Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B : A novel inhibitor of angiogenesis. In: Journal of Orthopaedic Science. 2011 ; Vol. 16, No. 4. pp. 443-450.
@article{ee7cde69f8d54661874298aaf2915205,
title = "Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: A novel inhibitor of angiogenesis",
abstract = "Background: We have previously reported that recombinant human plasminogen-related protein B (rPRP-B), a putative 9-kDa protein that closely resembles the activation peptide of plasminogen, has shown significant inhibition of tumor growth through inhibition of angiogenesis. Based on recent reports suggesting a close relationship between rheumatoid arthritis (RA) and angiogenesis, we hypothesized that this compound would regulate inflammatory conditions in RA. The present study therefore tested the effects of rPRP-B in the treatment of collagen-induced arthritis (CIA) to elucidate the mechanisms underlying these effects. Methods: DBA/1J mice immunized with type II collagen to induce CIA were monitored to assess the effects of rPRP-B on clinical severity of the disease. Pathological changes in joints, including vessel formation and vascular endothelial growth factor (VEGF) production, were examined histologically. Bone destruction was radiologically evaluated. In vitro studies on the effects of rPRP-B on cell proliferation and production of VEGF in interleukin (IL)-1β or basic fibroblast growth factor (bFGF)-stimulated human synoviocytes were also performed. Results: Development of CIA was effectively inhibited by rPRP-B. Radiological examinations revealed that the protein reduced bone destruction in CIA. CIA-induced vessel formation and VEGF expression in vivo were also reduced. In vitro mechanistic studies demonstrated that rPRP-B affected human synoviocyte proliferation and VEGF production stimulated by IL-1β and bFGF. Conclusions: Given the ability to effectively promote multistep anti-angiogenic activities, including cell growth inhibition and cytokine regulation, rPRP-B represents a promising candidate for a novel therapeutic agent against RA.",
author = "Koichiro Tanaka and Takeshi Morii and Lawrence Weissbach and Keisuke Horiuchi and Katsuhito Takeuchi and Yoshiaki Toyama and Hideo Morioka",
year = "2011",
month = "7",
doi = "10.1007/s00776-011-0091-x",
language = "English",
volume = "16",
pages = "443--450",
journal = "Journal of Orthopaedic Science",
issn = "0949-2658",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B

T2 - A novel inhibitor of angiogenesis

AU - Tanaka, Koichiro

AU - Morii, Takeshi

AU - Weissbach, Lawrence

AU - Horiuchi, Keisuke

AU - Takeuchi, Katsuhito

AU - Toyama, Yoshiaki

AU - Morioka, Hideo

PY - 2011/7

Y1 - 2011/7

N2 - Background: We have previously reported that recombinant human plasminogen-related protein B (rPRP-B), a putative 9-kDa protein that closely resembles the activation peptide of plasminogen, has shown significant inhibition of tumor growth through inhibition of angiogenesis. Based on recent reports suggesting a close relationship between rheumatoid arthritis (RA) and angiogenesis, we hypothesized that this compound would regulate inflammatory conditions in RA. The present study therefore tested the effects of rPRP-B in the treatment of collagen-induced arthritis (CIA) to elucidate the mechanisms underlying these effects. Methods: DBA/1J mice immunized with type II collagen to induce CIA were monitored to assess the effects of rPRP-B on clinical severity of the disease. Pathological changes in joints, including vessel formation and vascular endothelial growth factor (VEGF) production, were examined histologically. Bone destruction was radiologically evaluated. In vitro studies on the effects of rPRP-B on cell proliferation and production of VEGF in interleukin (IL)-1β or basic fibroblast growth factor (bFGF)-stimulated human synoviocytes were also performed. Results: Development of CIA was effectively inhibited by rPRP-B. Radiological examinations revealed that the protein reduced bone destruction in CIA. CIA-induced vessel formation and VEGF expression in vivo were also reduced. In vitro mechanistic studies demonstrated that rPRP-B affected human synoviocyte proliferation and VEGF production stimulated by IL-1β and bFGF. Conclusions: Given the ability to effectively promote multistep anti-angiogenic activities, including cell growth inhibition and cytokine regulation, rPRP-B represents a promising candidate for a novel therapeutic agent against RA.

AB - Background: We have previously reported that recombinant human plasminogen-related protein B (rPRP-B), a putative 9-kDa protein that closely resembles the activation peptide of plasminogen, has shown significant inhibition of tumor growth through inhibition of angiogenesis. Based on recent reports suggesting a close relationship between rheumatoid arthritis (RA) and angiogenesis, we hypothesized that this compound would regulate inflammatory conditions in RA. The present study therefore tested the effects of rPRP-B in the treatment of collagen-induced arthritis (CIA) to elucidate the mechanisms underlying these effects. Methods: DBA/1J mice immunized with type II collagen to induce CIA were monitored to assess the effects of rPRP-B on clinical severity of the disease. Pathological changes in joints, including vessel formation and vascular endothelial growth factor (VEGF) production, were examined histologically. Bone destruction was radiologically evaluated. In vitro studies on the effects of rPRP-B on cell proliferation and production of VEGF in interleukin (IL)-1β or basic fibroblast growth factor (bFGF)-stimulated human synoviocytes were also performed. Results: Development of CIA was effectively inhibited by rPRP-B. Radiological examinations revealed that the protein reduced bone destruction in CIA. CIA-induced vessel formation and VEGF expression in vivo were also reduced. In vitro mechanistic studies demonstrated that rPRP-B affected human synoviocyte proliferation and VEGF production stimulated by IL-1β and bFGF. Conclusions: Given the ability to effectively promote multistep anti-angiogenic activities, including cell growth inhibition and cytokine regulation, rPRP-B represents a promising candidate for a novel therapeutic agent against RA.

UR - http://www.scopus.com/inward/record.url?scp=80052507868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052507868&partnerID=8YFLogxK

U2 - 10.1007/s00776-011-0091-x

DO - 10.1007/s00776-011-0091-x

M3 - Article

VL - 16

SP - 443

EP - 450

JO - Journal of Orthopaedic Science

JF - Journal of Orthopaedic Science

SN - 0949-2658

IS - 4

ER -